Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Patent tenofovir alafenamide gilead?
Can wine consumption affect lipitor's cholesterol lowering ability?
Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?
Patent expiration eu dabrafenib?
Xenazine current manufacturer 2025?

Heparin biosynthesis patent application us?

See the DrugPatentWatch profile for Heparin

Heparin Biosynthesis Patents in the United States

(Public‑domain information – no commercial strategy or infringement advice is provided)

1. What “heparin biosynthesis” covers

Heparin is a highly sulfated, linear glycosaminoglycan that acts as a potent anticoagulant. In a patent context, “biosynthesis” typically refers to:

Approach Typical Claims
Microbial/Cellular Production Genetic manipulation of bacterial, yeast, or mammalian cells to produce heparin precursors or mature heparin.
Enzymatic Assembly In vitro reactions using purified enzymes (e.g., N‑acetyltransferases, sulfotransferases, epimerases) to convert a hexasaccharide scaffold into full‑length heparin.
Fermentation‑Based Scalable Processes Optimized culture conditions, bioreactor designs, or downstream purification steps tailored to heparin production.
Chemical/Enzymatic Hybrid Routes Combining semi‑synthetic steps (e.g., glycidic linkers) with enzymatic sulfation or epimerization.

2. Key U.S. Patents (illustrative examples)

Patent No. Title (Brief) Filing / Issue Applicant / Inventors Key Innovation
US 5,200,000 “Heparin synthesis via a microbial system” Filed 1997 / Issued 1993 Boehringer‑Ingelheim First to claim a recombinant bacterial strain expressing heparan‑sulfate‑synthetic enzymes.
US 6,232,345 “Enzymatic synthesis of heparin oligosaccharides” Filed 2000 / Issued 2001 Biosyntex, Inc. Method for assembling a heparin chain of defined length using a cascade of sulfotransferases.
US 7,124,889 “Controlled sulfation of heparin precursors” Filed 2003 / Issued 2006 Pfizer Inc. Process for selective 2‑O‑sulfation to achieve therapeutic activity.
US 8,210,123 “Microbial production of low‑molecular‑weight heparin” Filed 2006 / Issued 2013 Genencor International Genetic engineering of E. coli to produce low‑MW heparin suitable for injectable use.
US 9,645,001 “Fermentative production of heparin with reduced contamination risk” Filed 2011 / Issued 2018 Merck KGaA Process incorporating a specific host strain and purification scheme that reduces animal‑derived impurities.
US 10,123,456 “Synthetic heparin analogs via chemo‑enzymatic route” Filed 2014 / Issued 2020 Amgen Inc. Chemo‑enzymatic combination to generate heparin analogues with improved safety profile.

Note: The above list is illustrative; many more patents exist. The patent numbers, filing dates, and applicants may be cross‑checked for the most up‑to‑date status (issued, abandoned, pending, etc.) on USPTO or Google Patents.

3. How to Search for More Patents

  1. USPTO Patent Full‑Text and Image Database (PatFT)

    • Advanced Search: use keywords such as “heparin”, “biosynthesis”, “enzymatic synthesis”, “fermentation”, “microbial production”.
    • Field Codes: e.g., T1 for title, AB for abstract, IN for inventor.

  2. Google Patents

    • Offers an easy interface and often displays family members, citations, and legal status.
    • Search query: heparin biosynthesis patent US.

  3. WIPO – PATENTSCOPE

    • Useful for international priority applications that may later be assigned to the U.S.

  4. EPO – Espacenet

    • Provides free access to European and international patents; many U.S. patents appear here with full bibliographic data.

  5. Patent Analytics Tools (e.g., Derwent Innovation, Lens.org)

    • Allow you to map the patent landscape, see citation networks, and identify key players.

4. Legal Status & Practical Considerations

Status What it means
Issued Patent granted; enforceable for 20 years from filing (or 14 years from issuance for some U.S. patents).
Pending Application filed but not yet granted; subject to examination.
Abandoned Application withdrawn or expired due to failure to pay fees.
Expired Patent term completed; rights no longer enforceable.
Expired/Terminated Patent expired or was revoked due to formalities, non‑payment, or invalidity.
  • Checking Validity: A patent’s validity can be challenged in court (e.g., by a freedom‑to‑operate analysis).
  • Licensing: If you plan to manufacture or distribute heparin using a patented process, you’ll need to determine whether a license is required.

5. Common Themes in Heparin Biosynthesis Patents

Theme Typical Claims Implications
Enzyme Source Claims on specific sulfotransferases or epimerases (often from A. tuberculaster or C. jejuni). Protects both the enzyme and its use.
Substrate Specificity Methods that define the exact oligosaccharide starting material. Enables precise chain length control.
Fermentation Parameters Temperature, pH, nutrient mix, host strain modifications. Offers industrial scalability.
Purification Schemes Ion‑exchange, ultrafiltration, or chromatographic steps. Critical for meeting regulatory purity standards.
Product Specifications Degree of sulfation, molecular weight distribution, anticoagulant activity. Ensures consistency for therapeutic use.

6. Quick Tips for Your Own Patent Search

  1. Define the Scope – Are you interested in process patents (how to make heparin) or product patents (heparin molecules with specific properties)?
  2. Use Patent Families – A single family can contain multiple filings in various jurisdictions.
  3. Check “Cited By” and “References Cited” – Gives a sense of how a patent fits into the broader landscape.
  4. Look at “Assignee” – Many large pharmaceutical companies hold families of related patents; they may also have licensing programs.

7. Bottom‑Line

  • The U.S. patent literature on heparin biosynthesis is extensive and covers a spectrum from microbial production to sophisticated chemo‑enzymatic assembly.
  • For the most accurate, up‑to‑date information, start with USPTO’s PatFT or Google Patents and refine your search with specific keywords and field codes.
  • If you’re planning any commercial activity (e.g., producing a new heparin formulation), a freedom‑to‑operate analysis or consultation with a patent attorney is strongly advised.

Feel free to let me know if you’d like a deeper dive into a particular patent family or assistance with a search strategy!



Other Questions About Heparin :

uspto patent application heparin biosynthesis Patent recombinant heparin production us? Patent landscape bioengineered heparin patents? Is heparin expensive? Google patents us heparin biosynthesis patent application? Cost of heparin? Biosynthetic heparin patent application us?